Cdk4 Inhibitor is a cell-permeable, unsymmetrical indolocarbazole compound that displays antiproliferative properties. Acts as a potent, selective, and ATP-competitive inhibitor of Cdk4/cyclin D1 (IC50 = 76 nM). It inhibits the activity of other Cdk's only at much higher concentrations (IC50 = 520 nM and 2.1 μM for Cdk2/cyclin E and Cdc2 (Cdk1)/cyclin B, respectively) and shows little activity towards CaMKII, PKA, or GSK-3b (IC50 ≥ 12.4 μM). Shown to inhibit tumor cells growth (IC50 < 3.0 μM in HCT-116 and NCI-H460 cells) by blocking Rb phosphorylation and inducing G1 cell cycle arrest.
Zhu, G., et al. 2003. J. Med. Chem. 46, 2027.
See how others have used Cdk4 Inhibitor (CAS 546102-60-7). Click on the entry to view the PubMed entry .
PMID: # 25823926 2015. Oncotarget. 6: 8900-13.
PMID: # 25731732 2015. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 36: 5987-97.
PMID: # 21714634 Sakamoto, K. et al. 2011. J Ocul Pharmacol Ther. 27: 419-425.
PMID: # 31616959 Arch. Toxicol. 93: 3523-3534.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.